TRIAL DETAIL

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Drug:
Trial Name:
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Recruiting
Phase:
1
Start Date 06/01/2011
Age of Trial (yrs) 8.3
Treatment Phase:
Gleevec-resistant
Drug Category:
Immune stimulate
Strategy:
Stimulate the immune system
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
OSU-09138, NCI-2011-00920
Sponsor:
Ohio State University Comprehensive Cancer Center
Patient Contact:
Pravin T.P Kaumaya, PhD 614-292-7028 pravin.kaumaya@osumc.edu
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Trial Links

Trial Results

Drug Information

Hum Vaccin Immunother. 2015;11(6):1368-86. doi: 10.1080/21645515.2015.1026495.
 

Trial Sites

Name
Address
City
State
Zip
Country
Columbus
OH
43210
USA